Michael Mamounas

735 total citations
18 papers, 437 citations indexed

About

Michael Mamounas is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael Mamounas has authored 18 papers receiving a total of 437 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael Mamounas's work include Radiopharmaceutical Chemistry and Applications (3 papers), Cell death mechanisms and regulation (3 papers) and Prostate Cancer Treatment and Research (3 papers). Michael Mamounas is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (3 papers), Cell death mechanisms and regulation (3 papers) and Prostate Cancer Treatment and Research (3 papers). Michael Mamounas collaborates with scholars based in United States, France and Switzerland. Michael Mamounas's co-authors include Flossie Wong‐Staal, Ellis Englesberg, Mang Yu, Scott P. Kennedy, James Merson, Jack R. Barber, Gang Yu, Brian Leaker, Wayne J. Fairbrother and Harvey Wong and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Michael Mamounas

18 papers receiving 421 citations

Peers

Countries citing papers authored by Michael Mamounas

Since Specialization

Citations

This map shows the geographic impact of Michael Mamounas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Mamounas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Mamounas more than expected).

Fields of papers citing papers by Michael Mamounas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Mamounas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Mamounas. The network helps show where Michael Mamounas may publish in the future.

Co-authorship network of co-authors of Michael Mamounas

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Mamounas. A scholar is included among the top collaborators of Michael Mamounas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Mamounas. Michael Mamounas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Abstract P2-13-25: A phase I dose-escalation study of DHES0815A, a HER2-targeting antibody-drug conjugate with a DNA monoalkylator payload, in patients with HER2-positive breast cancer 2022 ·Cancer Research ·Ian E. Krop, Erika Hamilton, Kyung Hae Jung, Shanu Modi, Kevin Kalinsky, Gail D. Lewis Phillips, Rong Shi, Sharareh Monemi, Michael Mamounas, Ola M. Saad, Voleak Choeurng, (unknown), Eunpi Cho, Alexander Ungewickell, Patricia LoRusso	5
2	Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer 2019 ·Journal of Clinical Oncology ·Daniel C. Danila, Russell Z. Szmulewitz, Ulka N. Vaishampayan, Celestia S. Higano, Ari David Baron, Houston Gilbert, Flávia Brunstein, (unknown), Bei Wang, Omar Kabbarah, Michael Mamounas, Bernard M. Fine, Daniel Maslyar, Alexander Ungewickell, Howard I. Scher	59
3	A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors 2016 ·Clinical Cancer Research ·Anthony W. Tolcher, Johanna C. Bendell, Kyriakos P. Papadopoulos, Howard A. Burris, Amita Patnaik, Wayne J. Fairbrother, Harvey Wong, Nageshwar Budha, Walter C. Darbonne, Franklin Peale, Michael Mamounas, Stephanie Royer‐Joo, Ron Yu, Chia C. Portera, Jeffrey R. Infante	26
4	Abstract 4310: Predictive biomarkers of tumor sensitivity to STEAP1 antibody-drug conjugate (ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) 2015 ·Cancer Research ·Daniel C. Danila, Howard I. Scher, Edith Szafer‐Glusman, (unknown), (unknown), Martin Fleisher, Nicole A. Schreiber, Kristen Curtis, Houston Gilbert, Daniel Maslyar, Bernard M. Fine, Ron Firestein, Michael Mamounas, Mark R. Lackner, Omar Kabbarah	1
5	STEAP1 as a predictive biomarker for antibody-drug conjugate (ADC) activity in metastatic castration resistant prostate cancer (mCRPC). 2015 ·Journal of Clinical Oncology ·Daniel C. Danila, Martin Fleisher, Jorge A. Carrasquillo, Houston Gilbert, Michael J. Morris, (unknown), (unknown), Edith Szafer‐Glusman, (unknown), Chintan Patel, Nicole A. Schreiber, Kristen Curtis, Daniel Maslyar, Vanessa Lemahieu, Bernard M. Fine, Michael Mamounas, Alexander Ungewickell, Mark R. Lackner, Howard I. Scher, Omar Kabbarah	4
6	Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist 2013 ·Drug Metabolism and Disposition ·Harvey Wong, Stephen E. Gould, Nageshwar Budha, Walter C. Darbonne, Edward E. Kadel, Hank La, Bruno Alicke, Jason Halladay, Rebecca J. Erickson, Chia C. Portera, Anthony W. Tolcher, J. Infante, Michael Mamounas, John A. Flygare, Cornelis E. C. A. Hop, Wayne J. Fairbrother	42
7	Phase I study of safety and pharmacokinetics (PK) of GDC-0917, an antagonist of inhibitor of apoptosis (IAP) proteins in patients (Pts) with refractory solid tumors or lymphoma. 2013 ·Journal of Clinical Oncology ·Anthony W. Tolcher, Kyriakos P. Papadopoulos, Amita Patnaik, Wayne J. Fairbrother, Harvey Wong, Nageshwar Budha, Walter C. Darbonne, Franklin Peale, Michael Mamounas, Stephanie Royer‐Joo, Ron Yu, Chia C. Portera, Johanna C. Bendell, Howard A. Burris, Jeffrey R. Infante	13
8	Dogs Are More Sensitive to Antagonists of Inhibitor of Apoptosis Proteins Than Rats and Humans: A Translational Toxicokinetic/Toxicodynamic Analysis 2012 ·Toxicological Sciences ·Harvey Wong, Nageshwar Budha, Kristina West, Elizabeth Blackwood, Joseph A. Ware, Ron Yu, Walter C. Darbonne, Stephen E. Gould, Ronald W. Steigerwalt, Rebecca J. Erickson, (unknown), Patricia LoRusso, S. Gail Eckhardt, Andrew J. Wagner, Iris T. Chan, Michael Mamounas, John A. Flygare, Wayne J. Fairbrother	13
9	Toxicity Profile of Small-Molecule IAP Antagonist GDC-0152 Is Linked to TNF-α Pharmacology 2012 ·Toxicological Sciences ·(unknown), Jacqueline M. Tarrant, Gary Cain, Sock-Cheng Lewin-Koh, Noël Dybdal, Harvey Wong, Elizabeth Blackwood, Kristina West, Ronald W. Steigerwalt, Michael Mamounas, John A. Flygare, (unknown), Donna M. Dambach, Wayne J. Fairbrother, (unknown)	28
10	152 The novel highly selective and efficacious MET inhibitor BAY853474: mode of action, basic in vitro characteristics and preclinical pharmacology 2010 ·European Journal of Cancer Supplements ·Dieter Zopf, Maria Kissel, Michael Mamounas, Kathleen Schuck, (unknown), Ulf Bömer, Holger Hess‐Stumpp, Philip Lienau, (unknown)	1
11	Establishment of a highly sensitive Taqman-based assay for non-invasively detecting biomarkers expressed in circulating tumor cells in human and mouse whole blood. 2007 ·Cancer Research ·(unknown), Sandra L. Biroc, Robert Radeke, GU Jian-ming, Ted Lau, Michael Mamounas	2
12	Inhibition of CCR5-Dependent HIV-1 Infection by Hairpin Ribozyme Gene Therapy against CC-Chemokine Receptor 5 2000 ·Virology ·Yu Feng, Mark C. Leavitt, Richard Tritz, E A Duarte, David E. Kang, Michael Mamounas, (unknown), Flossie Wong‐Staal, Scott P. Kennedy, James Merson, Mang Yu, Jack R. Barber	51
13	Development of Novel Cell Surface CD34-Targeted Recombinant Adenoassociated Virus Vectors for Gene Therapy 1998 ·Human Gene Therapy ·(unknown), Michael Mamounas, Gang Yu, Scott P. Kennedy, Brian Leaker, James Merson, Flossie Wong‐Staal, Mang Yu, Jack R. Barber	96
14	An infectious chimeric human immunodeficiency virus type 2 (HIV-2) expressing the HIV-1 principal neutralizing determinant 1995 ·Journal of Virology ·Michael Mamounas, David J. Looney, Randy Talbott, Flossie Wong‐Staal	5
15	Increased titer of recombinant AAV vectors by gene transfer with adenovirus coupled to DNA-polylysine complexes. 1995 ·PubMed ·Michael Mamounas, Matthew L. Leavitt, Min Yu, Flossie Wong‐Staal	22
16	Analysis of the genes involved in the insulin transmembrane mitogenic signal in Chinese hamster ovary cells, CHO-K1, utilizing insulin-independent mutants. 1991 ·Proceedings of the National Academy of Sciences ·Michael Mamounas, Sandra L. Ross, Christina Luong, E H Brown, (unknown), Graeme J. Carroll, Ellis Englesberg	15
17	The insulin receptor as a transmitter of a mitogenic signal in Chinese hamster ovary CHO-K1 cells. 1989 ·Proceedings of the National Academy of Sciences ·Michael Mamounas, (unknown), Ellis Englesberg	30
18	A defined medium for and the effect of insulin on the growth, amino acid transport, and morphology of chinese hamster ovary cells, CHO-K1 (CCL 61) and the isolation of insulin “independent” mutants 1986 ·In Vitro Cellular & Developmental Biology - Plant ·Elizabeth A. Mendiaz, Michael Mamounas, John R. Moffett, Ellis Englesberg	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact